Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P84243

UPID:
H33_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P84243; P06351; P33155; Q5VV55; Q5VV56; Q66I33; Q9V3W4

BACKGROUND:
The protein Histone H3.3, with the recommended name encoded by P84243, serves as an epigenetic imprint of transcriptionally active chromatin. It constitutes the predominant form of histone H3 in non-dividing cells, playing a central role in limiting DNA accessibility and thereby regulating transcription, DNA repair, replication, and stability. Its deposition at sites of nucleosomal displacement throughout transcribed genes underscores its critical function in gene expression.

THERAPEUTIC SIGNIFICANCE:
Involvement of Histone H3.3 in gliomas and Bryant-Li-Bhoj neurodevelopmental syndromes underscores its therapeutic significance. Mutations in Histone H3.3 lead to tumorigenesis by altering histone methylation and epigenetic regulation of gene expression. Targeting the pathways influenced by Histone H3.3 mutations presents a promising avenue for developing treatments for these diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.